Abstract 17138: Intracoronary Infusion of Bone Marrow-derived Selected CD34+CXCR4+ cells and Non-selected Mononuclear Cells in Patients With Acute STEMI and Reduced Left Ventricular Ejection Fraction. 5-year Follow-up of Randomized, Multicenter Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial
REGENT trial was designed to compare efficacy and safety of intracoronary bone marrow (BM)-derived unselected mononuclear cells (MNC) and selected CD34+CXCR4+ cells (CD34CXCR4) in patients with first acute myocardial infarction (MI) and reduced <40% left ventricular ejection fraction (LVEF).
Methods: 200 patients were randomly assigned to intracoronary infusion of MNC (n=80) or CD34CXCR4 (n=80) cells or standard treatment (control, CTRL). Primary end-point: change of LVEF and LV volumes measured by MRI after 6 months.
Results: LVEF increased from baseline to 6 months by 3% (p=0.01) in patients receiving MNC, 3% in CD34CXCR4 (p=0.04) and remained unchanged in CTRL (p=0.73), although the differences between the groups were not significant. No significant differences in changes of LV volumes were found between groups. Significant increase of LVEF was observed only in patients receiving BM cells who had baseline LVEF < median (37%). There were no differences in major cardiovascular event (death, reinfarction, stroke, TVR) between groups. Complete 5-years follow-up of the patients enrolled into REGENT trial will be presented.
- © 2013 by American Heart Association, Inc.